Cempra, Inc. (CEMP) Expected to Announce Quarterly Sales of $2.99 Million

Brokerages forecast that Cempra, Inc. (NASDAQ:CEMP) will announce sales of $2.99 million for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Cempra’s earnings, with estimates ranging from $880,000.00 to $4.55 million. Cempra reported sales of $3.97 million in the same quarter last year, which indicates a negative year-over-year growth rate of 24.7%. The firm is scheduled to announce its next quarterly earnings report on Thursday, October 26th.

According to Zacks, analysts expect that Cempra will report full year sales of $2.99 million for the current financial year, with estimates ranging from $7.50 million to $15.33 million. For the next fiscal year, analysts forecast that the company will post sales of $13.96 million per share, with estimates ranging from $5.00 million to $25.49 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Cempra.

Cempra (NASDAQ:CEMP) last issued its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.09. The business had revenue of $0.86 million for the quarter, compared to analysts’ expectations of $3.58 million. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The firm’s quarterly revenue was down 74.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.51) EPS.

Several analysts have issued reports on CEMP shares. Zacks Investment Research raised Cempra from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a report on Friday, August 11th. Stifel Nicolaus reissued a “hold” rating and set a $4.00 price target on shares of Cempra in a report on Thursday, August 10th. Jefferies Group LLC reissued a “hold” rating and set a $3.00 price target on shares of Cempra in a report on Thursday, September 14th. Finally, Roth Capital lowered Cempra from a “buy” rating to a “neutral” rating and cut their price target for the company from $8.00 to $4.00 in a report on Thursday, August 10th. Four investment analysts have rated the stock with a sell rating, twelve have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Cempra has an average rating of “Hold” and an average price target of $10.00.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CEMP. Teachers Advisors LLC boosted its stake in shares of Cempra by 5.2% in the fourth quarter. Teachers Advisors LLC now owns 93,481 shares of the biotechnology company’s stock worth $262,000 after acquiring an additional 4,632 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Cempra by 6.0% in the first quarter. Bank of New York Mellon Corp now owns 206,840 shares of the biotechnology company’s stock worth $776,000 after buying an additional 11,760 shares in the last quarter. UBS Asset Management Americas Inc. purchased a new stake in shares of Cempra in the first quarter worth about $140,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Cempra in the first quarter worth about $314,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cempra in the first quarter worth about $187,000. 49.75% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/09/cempra-inc-cemp-expected-to-announce-quarterly-sales-of-2-99-million.html.

Shares of Cempra (NASDAQ CEMP) opened at 3.175 on Monday. Cempra has a one year low of $2.55 and a one year high of $24.48. The company’s 50-day moving average price is $3.07 and its 200-day moving average price is $3.74. The stock’s market cap is $166.71 million.

About Cempra

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Get a free copy of the Zacks research report on Cemp

According to Zacks, analysts expect that Cempra will report full year sales of $2.99 million for the current financial year, with estimates ranging from $7.50 million to $15.33 million. For the next fiscal year, analysts forecast that the company will post sales of $13.96 million per share, with estimates ranging from $5.00 million to $25.49 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Cempra.

Cempra (NASDAQ:CEMP) last issued its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.09. The business had revenue of $0.86 million for the quarter, compared to analysts’ expectations of $3.58 million. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The firm’s quarterly revenue was down 74.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.51) EPS.

Several analysts have issued reports on CEMP shares. Zacks Investment Research raised Cempra from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a report on Friday, August 11th. Stifel Nicolaus reissued a “hold” rating and set a $4.00 price target on shares of Cempra in a report on Thursday, August 10th. Jefferies Group LLC reissued a “hold” rating and set a $3.00 price target on shares of Cempra in a report on Thursday, September 14th. Finally, Roth Capital lowered Cempra from a “buy” rating to a “neutral” rating and cut their price target for the company from $8.00 to $4.00 in a report on Thursday, August 10th. Four investment analysts have rated the stock with a sell rating, twelve have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Cempra has an average rating of “Hold” and an average price target of $10.00.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CEMP. Teachers Advisors LLC boosted its stake in shares of Cempra by 5.2% in the fourth quarter. Teachers Advisors LLC now owns 93,481 shares of the biotechnology company’s stock worth $262,000 after acquiring an additional 4,632 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Cempra by 6.0% in the first quarter. Bank of New York Mellon Corp now owns 206,840 shares of the biotechnology company’s stock worth $776,000 after buying an additional 11,760 shares in the last quarter. UBS Asset Management Americas Inc. purchased a new stake in shares of Cempra in the first quarter worth about $140,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Cempra in the first quarter worth about $314,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cempra in the first quarter worth about $187,000. 49.75% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/09/cempra-inc-cemp-expected-to-announce-quarterly-sales-of-2-99-million.html.

Shares of Cempra (NASDAQ CEMP) opened at 3.175 on Monday. Cempra has a one year low of $2.55 and a one year high of $24.48. The company’s 50-day moving average price is $3.07 and its 200-day moving average price is $3.74. The stock’s market cap is $166.71 million.

About Cempra

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Get a free copy of the Zacks research report on Cempra (CEMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cempra (NASDAQ:CEMP)

Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply